List of works - Jeremie Guedj

A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.

scientific article

Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model

scientific article

Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.

scientific article published on 27 March 2018

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates

scientific article published in 2022

Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up

scientific article published on 05 July 2019

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

scientific article published in 2021

Can we use viral kinetic models to individualize treatment?

scientific article

Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

scientific article published on 5 April 2016

Design evaluation and optimization for models of hepatitis C viral dynamics.

scientific article published on 21 February 2011

Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults

scientific article published on 28 December 2015

Determining Ribavirin's mechanism of action against Lassa virus infection

scientific article published on 15 September 2017

Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection.

scientific article

Dose regimen of favipiravir for Ebola virus disease

scientific article published on 28 November 2014

Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b).

scientific article

Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates

scientific article published on 29 March 2021

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

scientific article

Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies

scientific article published in Nature Communications

Ebola virus dynamics in mice treated with favipiravir

scientific article published on 2 September 2015

Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.

scientific article published on 08 February 2013

Estimating biologically relevant parameters under uncertainty for experimental within-host murine West Nile virus infection.

scientific article published on 13 April 2016

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

scientific article

Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses

scientific article published on 10 October 2016

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

scientific article

Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.

scientific article published on July 2011

Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)

scientific article published on 15 February 2012

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

scientific article published on 22 July 2020

Impact of treatment against hepatitis C virus on overall survival of naive patients with advanced liver disease

scientific article

Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection

scientific article

Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin

scientific article published on 07 January 2021

Mathematical modeling of bacterial kinetics to predict the impact of antibiotic colonic exposure and treatment duration on the amount of resistant enterobacteria excreted

scientific article (publication date: September 2014)

Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?

scientific article published on 5 October 2012

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

scientific article

Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients

scientific article published on April 2014

Modelling hepatitis C therapy--predicting effects of treatment

scientific article

Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.

scientific article published on 10 November 2015

Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients.

scientific article

NIMROD: a program for inference via a normal approximation of the posterior in models with random effects based on ordinary differential equations

scientific article

Nonlinear Mixed-effect Models for Prostate-specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: A Comparison by Simulation of Two-stage and Joint Approaches.

scientific article

Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study

scientific article published on 25 December 2014

Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study

scientific article published on January 2017

Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate

scientific article

Reply: To PMID 25098971.

scientific article published on 18 April 2015

Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.

scientific article

Umbilical artery Doppler assessment: a clear disparity in ultrasound practice in a national survey.

scientific article

Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling

scientific article

Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies

scientific article

Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients

scientific article

List of works by Jeremie Guedj

A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.

Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model

Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates

Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

Can we use viral kinetic models to individualize treatment?

Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

Design evaluation and optimization for models of hepatitis C viral dynamics.

Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults

Determining Ribavirin's mechanism of action against Lassa virus infection

Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection.

Dose regimen of favipiravir for Ebola virus disease

Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b).

Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies

Ebola virus dynamics in mice treated with favipiravir

Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.

Estimating biologically relevant parameters under uncertainty for experimental within-host murine West Nile virus infection.

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.

Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

Impact of treatment against hepatitis C virus on overall survival of naive patients with advanced liver disease

Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection

Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin

Mathematical modeling of bacterial kinetics to predict the impact of antibiotic colonic exposure and treatment duration on the amount of resistant enterobacteria excreted

Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients

Modelling hepatitis C therapy--predicting effects of treatment

Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.

Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients.

NIMROD: a program for inference via a normal approximation of the posterior in models with random effects based on ordinary differential equations

Nonlinear Mixed-effect Models for Prostate-specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: A Comparison by Simulation of Two-stage and Joint Approaches.

Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study

Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study

Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate

Reply: To PMID 25098971.

Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.

Umbilical artery Doppler assessment: a clear disparity in ultrasound practice in a national survey.

Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling

Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies

Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients

Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making